
Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study of Measles and Rubella Vaccination using Vaxxas’ High Density Micro-Array Patch
Funding Accelerates Vaxxas’ Clinical Pipeline of Innovative Vaccines CAMBRIDGE, Mass. & BRISBANE, Australia–(BUSINESS WIRE)–Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that […]
